Cadila Healthcare gains on launching Zolmitriptan in US market

17 May 2013 Evaluate

Cadila Healthcare is currently trading at Rs. 841.75, up by 5.95 points or 0.71% from its previous closing of Rs. 835.80 on the BSE.

The scrip opened at Rs. 835.80 and has touched a high and low of Rs. 845.00 and Rs. 835.80 respectively.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 964.00 on 12-Sep-2012 and a 52 week low of Rs. 705.05 on 04-Jun-2012.

Last one week high and low of the scrip stood at Rs. 846.80 and Rs. 771.00 respectively. The current market cap of the company is Rs. 17,234.00 crore.

The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 16.53 % and 8.68 % respectively.

Cadila Healthcare has declared the first day launch of Zolmitriptan orally disintegrating tablets upon receiving the final approval from the US Food and Drug Administrator (USFDA). The drug is used in the treatment of migraine, has an estimated sale of $175 million in 2012 as per IMS.

The company would market the product in the strengths of 2.5 mg and 5mg in the US market. The group now has 79 approvals and has so far filed 173 ANDAs since the commencement of the filing process in FY 2003-04.

The flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×